Keyword: Takeda

Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.

A jury ordered Takeda, which just scooped up Shire, to pay $155 million for stepping on Bayer's hemophilia patent.

Takeda withdrew an FDA filing for Ninlaro in post-transplant maintenance because it doesn't yet have survival data the agency wants.

Takeda's dengue vaccine clears phase 3; Pfizer launches China's first pay-for-performance deal in oncology; Aslan cuts 30% of its workforce.

Takeda's dengue shot met its goal in a pivotal phase 3 study that covered eight countries and more than 20,000 participants.

Sun Pharma drops to six-year low; Takeda looks to sell emerging markets products; Immunochina raises $20 million for CAR-T push.

Roche has the pipeline it needs for growth, its chairman said, but the company could add on with small- or medium-sized M&A.

Emerging markets have been holding Takeda back, despite double-digit growth in China. Now, the company could reap some cash by selling some of those products.

Pfizer closes two Hospira plants in India; Gilead licenses Yuhan's NASH programs; Fujifilm is expanding its footprint in the U.S.

Takeda will probably not sell its OTC business to help pay off the $31 billion loan it’s taking to finance the Shire takeover, its CEO says.